Formulación y evaluación de la suspensión oral de estiripentol
DOI:
https://doi.org/10.30827/ars.v66i3.31529Palabras clave:
Estiripentol, suspensión, viscosidad, volumen de sedimentación, potencial zetaResumen
Introduction: The current research work was carried out to develop a stable and effective suspension of stiripentol for treating epilepsy.
Method: FT-IR study was used to evaluate the compatibility between drug and excipient and the physical appearance of drug and excipient mixture was also examined after one month of stability study. The suspension was prepared by a mechanical stirrer and evaluated for viscosity, pH, sedimentation volume, zeta potential and in-vitro drug release studies. The optimized formulation was further evaluated for zeta potential and polydispersity index.
Results: FT-IR results confirmed the compatibility of drug and excipients. The physical appearance of the mixture was not altered during the accelerated storage conditions. Viscosity, pH and sedimentation volume of formulation ranged between 22.92 ±1.2 to 54.8 ± 2.1 cPs, 5.32 ± 0.04 to 6.01 ± 0.1 and 83.19 ± 0.9 % to 98.87 ± 1.2 % respectively. The zeta potential and polydispersity index of the optimized formulation was -52.1 mV and 0.198 respectively. These results were indicative of stable monodispersed suspension. The optimized formulation was stable at higher temperatures, humidity and in the presence of light, indicative of good shelf-life.
Conclusions: The study demonstrated that stiripentol oral suspension can be formulated as a stable and effective dosage form for the treatment of epilepsy.
Descargas
Citas
Hameed Z, Saleem S, Mirza J, Mustafa MS,Qamar Ul I. Characterisation of ictal and interictal states of epilepsy: A system dynamic approach of principal dynamic modes analysis. PLoS One. 2018; 13(1):e0191392. doi:10.1371/journal.pone.0191392. DOI: https://doi.org/10.1371/journal.pone.0191392
Rho JM,Sankar R. The pharmacologic basis of antiepileptic drug action. Epilepsia. 1999; 40(11):1471-83. DOI: https://doi.org/10.1111/j.1528-1157.1999.tb02029.x
Fisher JL. The effects of stiripentol on GABA(A) receptors. Epilepsia. 2011; 52 Suppl 2(2):76-8. doi:10.1111/j.1528-1167.2011.03008.x. DOI: https://doi.org/10.1111/j.1528-1167.2011.03008.x
Uchida Y, Terada K, Madokoro Y, et al. Stiripentol for the treatment of super-refractory status epilepticus with cross-sensitivity. Acta Neurol Scand. 2018; 137(4):432-37. doi:10.1111/ane.12888. DOI: https://doi.org/10.1111/ane.12888
Chiron C, Chemaly N, Chancharme L,Nabbout R. Initiating stiripentol before 2 years of age in patients with Dravet syndrome is safe and beneficial against status epilepticus. Dev Med Child Neurol. 2023; 65(12):1607-16. doi:10.1111/dmcn.15638. DOI: https://doi.org/10.1111/dmcn.15638
Wheless J,Weatherspoon S. Use of Stiripentol in Dravet syndrome: A guide for clinicians. Pediatr Neurol. 2024; doi:10.1016/j.pediatrneurol.2024.10.015. DOI: https://doi.org/10.1016/j.pediatrneurol.2024.10.015
Wang Y, Xu S, Xiao Z, et al. Stiripentol enteric solid dispersion-loaded effervescent tablets: Enhanced dissolution, stability, and absorption. AAPS PharmSciTech. 2022; 23(5):141. doi:10.1208/s12249-022-02261-5. DOI: https://doi.org/10.1208/s12249-022-02261-5
Vázquez-Blanco S, González-Freire L, Dávila-Pousa MC,Crespo-Diz C. pH determination as a quality standard for the elaboration of oral liquid compounding formula. Farm Hosp. 2018; 42(6):221-27. doi:10.7399/fh.10932.
Oppong EE, Osei-Asare C,Klu MW. Evaluation of the suspending properties of shea tree gum. Int J Pharm Pharm Sci. 2016; 8(7):409-13.
Shah PP,Mashru RC. Formulation and evaluation of taste masked oral reconstitutable suspension of primaquine phosphate. AAPS PharmSciTech. 2008; 9(3):1025-30. doi:10.1208/s12249-008-9137-6. DOI: https://doi.org/10.1208/s12249-008-9137-6
Giupponi G,Pagonabarraga I. Determination of the zeta potential for highly charged colloidal suspensions. Philos Trans A Math Phys Eng Sci 2011; 369(19):2546-54. doi:10.1098/rsta.2011.0024. DOI: https://doi.org/10.1098/rsta.2011.0024
Patel MS, Patel AD,Damor S. Design and development of dual release reconstitutable oral suspension of cefpodoxime proxetil for pediatric patient using risk-based quality by design approach. J Pharm Innov. 2022; 17(3):955-78. doi:10.1007/s12247-021-09577-y. DOI: https://doi.org/10.1007/s12247-021-09577-y
Rahman MS, Hasan MS, Nitai AS, et al. Recent developments of carboxymethyl cellulose. Polymers. 2021; 13(8):1345. doi: 10.3390/polym13081345 DOI: https://doi.org/10.3390/polym13081345
Almutairi M, D R L, Ghabbour H, Joe IH,Attia M. Spectroscopic identification, structural features, Hirshfeld surface analysis and molecular docking studies on stiripentol: An orphan antiepileptic drug. Journal of Molecular Structure. 2018; 1180(1):doi:10.1016/j.molstruc.2018.11.088. DOI: https://doi.org/10.1016/j.molstruc.2018.11.088
Pongjanyakul T,Puttipipatkhachorn S. Polymer-magnesium aluminum silicate composite dispersions for improved physical stability of acetaminophen suspensions. AAPS PharmSciTech. 2009; 10(2):346-54. doi:10.1208/s12249-009-9215-4. DOI: https://doi.org/10.1208/s12249-009-9215-4
Attebäck M, Hedin B,Mattsson S. Formulation optimization of extemporaneous oral liquids containing naloxone and propranolol for pediatric use. Sci Pharm. 2022; 90(1):15. doi:10.3390/scipharm90010015. DOI: https://doi.org/10.3390/scipharm90010015
Owusu FW, Asare CO, Enstie P, et al. Formulation and in vitro evaluation of oral capsules and suspension from the ethanolic extract of cola nitida seeds for the treatment of diarrhea. Biomed Res Int. 2021; 2021(1):1-7. doi:10.1155/2021/6630449. DOI: https://doi.org/10.1155/2021/6630449
Cheng Z, Kandekar U, Ma X, et al. Optimizing fluconazole-embedded transfersomal gel for enhanced antifungal activity and compatibility studies. Front Pharmacol. 2024; 15(1):1353791. DOI: https://doi.org/10.3389/fphar.2024.1353791
Júnior JAA,Baldo JB. The behavior of zeta potential of silica suspensions. New J GC. 2014; 4(02):1-9. doi:10.4236/njgc.2014.42004. DOI: https://doi.org/10.4236/njgc.2014.42004
Adeleke OA, Hayeshi RK,Davids H. Development and evaluation of a reconstitutable dry suspension containing isoniazid for flexible pediatric dosing. Pharmaceutics. 2020; 12(3):286. DOI: https://doi.org/10.3390/pharmaceutics12030286
Santoveña A, Suárez-González J, Martín-Rodríguez C,Fariña JB. Formulation design of oral pediatric Acetazolamide suspension: dose uniformity and physico-chemical stability study. Pharm Dev Technol. 2017; 22(2):191-97. doi:10.1080/10837450.2016.1175475. DOI: https://doi.org/10.1080/10837450.2016.1175475
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2025 Ujjwala Kandekar, Dinesh Bitale, Limbaji Chounde, Ajit Gaikwad
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
Los artículos que se publican en esta revista están sujetos a los siguientes términos en relación a los derechos patrimoniales o de explotación:
- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, la cual se distribuirá con una licencia Creative Commons BY-NC-SA 4.0 que permite a terceros reutilizar la obra siempre que se indique su autor, se cite la fuente original y no se haga un uso comercial de la misma.
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la fuente original de su publicación.
- Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en repositorios institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).
